Can a JAK-Inhibitor cream recolor white patches caused by cancer treatment?
NCT ID NCT07725432
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This study tests whether a topical cream containing ruxolitinib can safely restore skin color in people who develop white patches (vitiligo-like depigmentation) as a side effect of cancer immunotherapy. The cream is applied twice daily for 52 weeks. Researchers will measure how much color returns to the face and body. The trial includes 34 adults with at least 5% body surface area affected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a topical cream containing ruxolitinib, a JAK inhibitor
- What this could lead to
- If effective, this cream could become the first approved treatment for white patches caused by cancer immunotherapy, helping restore skin color.
- What could go wrong
- This is a small, early-phase trial with only 34 participants. Previous studies in other forms of vitiligo showed improvement in about half of patients, but results may differ for this specific cause.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-RELATED VITILIGO-LIKE-DEPIGMENTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universitätsspital Zürich
Zurich, 8058, Switzerland